RecruitingNot ApplicableNCT06456541

Infant Formula in Infants and Children With Cow's Milk Allergy

Determination of Hypoallergenicity of an Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy


Sponsor

Abbott Nutrition

Enrollment

61 participants

Start Date

Oct 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a multi-center, randomized, double-blinded, placebo-controlled food challenge to be conducted in infants and children with confirmed IgE-mediated cow's milk allergy (CMA), followed by a 7-day open feeding of the experimental formula.


Eligibility

Min Age: 3 MonthsMax Age: 12 Years

Inclusion Criteria10

  • Participant's parent(s) is/are willing for their child to undergo confirmatory testing or must have had at least one of the following within 6 months of enrollment:
  • Physician diagnosis of IgE-mediated CMA, according to the participant's clinical history (e.g. gastrointestinal symptoms, hives, respiratory symptoms or angioedema) AND, detectable serum milk-specific IgE \>0.7 kUᴀ/L or positive skin prick test wheal ≥5 mm;
  • Documentation of milk-specific serum IgE \>15 kUᴀ/L or \> 5 kUᴀ/L if younger than 1 year;
  • Documented cow's milk skin prick test wheal \>10mm;
  • Physician-supervised oral food challenge that elicited immediate, objective, allergic symptoms.
  • Participant's parent(s) agree for their child to stop oral steroid use within 14 days and antihistamine use within 7 days prior to confirmation of diagnosis and food challenges.
  • Participant had followed a strict cow's milk protein-free diet for at least 2 weeks prior to enrollment.
  • Parent(s) confirm their intention not to administer any products containing cow's milk protein during the study.
  • Participant is between 3 months and 12 years of age at enrollment.
  • Participant's parent(s) has voluntarily signed and dated an Informed Consent Form (ICF), approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.

Exclusion Criteria8

  • Participant is partially or exclusively breastfed at the time of enrollment.
  • Participant is consuming an amino acid-based formula due to failure on an extensively hydrolyzed formula.
  • Significant chronic medical diseases including major chromosomal or congenital anomalies, gastrointestinal diseases, or abnormalities other than CMA, immunodeficiencies, unstable asthma, eczema and/or food allergies treated with biologics (omalizumab or other monoclonal antibody), FPIES, eosinophilic esophagitis, and severe uncontrolled eczema.
  • Previous severe anaphylactic reaction to cow's milk within the last two years.,
  • An adverse medical history or current condition that is thought by the investigator to have potential for effects on tolerance or the hypoallergenicity test.
  • Participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent.
  • Participant is consuming baked milk products.
  • Use of and/or changing dose of high potency steroids.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERExperimental Extensively Hydrolyzed Formula

Experimental powder formula

OTHERPlacebo Extensively Hydrolyzed Formula

Placebo powder formula


Locations(8)

Children's Hospital Colorado

Aurora, Colorado, United States

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

University of Michigan Food Allergy Clinic

Ann Arbor, Michigan, United States

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

Nationwide Children's Hospital

Columbus, Ohio, United States

UT Southwestern Medical Center

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06456541


Related Trials